Clinical Trial Update: A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of aficamten versus placebo in adults with symptomatic non-obstructive hypertrophic cardiomyopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy
• Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Drugs mentioned

• Aficamten (aficamten)

Snippet

Sponsor: Cytokinetics | Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | Phase 3 | Status: ACTIVE_NOT_RECRUITING